I-Byte Healthcare Industry

IT Shades
I-Bytes Engage & Enable
HeAlthcare
September Edition
Email us - solutions@itshades.com
Website : www.itshades.com
IT Shades
Engage & Enable
About Us
Who We are
ITShades.com has been founded with singular aim of engaging and

enabling the best and brightest of businesses, professionals and students
with opportunities, learnings, best practices, collaboration and innovation
from IT industry.
Aim of this IByte
This document brings together a set of latest data points and

publicly available information relevant for Healthcare Industry.
We are very excited to share this content and believe that readers
will benefit immensely from this periodic publication immensely.
Reasons to talk to us
1. Publishing of your company’s solutions/announcements in this document.

2. Subscribe to this and other periodic publications i.e. I-Bytes, Solution Letters
from ITShades.com.
3. For placement of your company's click-able logo and advertisements.
4. Feedback for us to improve the content and format of these periodic
publications.
Feel free to contact us at marketing@itshades.com for any queries

IT Shades
Engage & Enable
Sponsoring Companies for this Edition
solutions@itshades.com
Advertise your Logo Below
LOGO 1 LOGO 2
LOGO 5
LOGO 3 LOGO 4

IT Shades
Engage & Enable
Table of Content s
1. Financial Updates.....................................................1
2.Solutions Updates......................................................7
3.Rewards and Recognition Updates........................14
4.Partnership Ecosystem Updates............................23
5.Miscellaneous Updates...........................................34

IT Shades
Engage & Enable
Financial, M&A Updates

Healthcare Industry

IT Shades
Engage & Enable
FosunPharma Release 2019 Interim Results：Continue to Increase R&D Investment

with a Steady Growth in Pharmaceutical Manufacturing & R&D Segment
Key Financial Highlights

1
• The revenue of the Group increased by 19.51% as compared to the corresponding period in 2018 to
RMB14,173 million.
• The pharmaceutical manufacturing and R&D segment of the Group generated revenue of RMB10,895
million, representing an increase of 21.65% as compared to the corresponding period of 2018.
• The revenue from healthcare service segment amounted to RMB1,460 million, an increase of 21.56%
compared with the corresponding period in 2018.
• The sales of the Group grew and the receivables’ collection was good. As a result, cash flow from
operating activities continued to show a rising trend. Net cash flow from operating activities amounted to
RMB1,450 million, representing an increase of 13.40% as compared to the corresponding period of 2018.
• The total profits and net profits of the Group amounted to RMB2,196 million and RMB1,820 million,
respectively, representing an increase of 7.78% and 4.70% as compared to the corresponding period of
2018, respectively. The result for the second quarter and for the first half of 2019 has been improved
compared with the first quarter 2019 and the second half of 2018 respectively.
Executive Commentary
“The pharmaceutical industry experienced a transformation and FosunPharma
will be firmly committed to the path of innovation and internationalization. We
believe that our efforts in innovation will help FosunPharma realize its
innovation transformation. The steady international-oriented development will
make us more competitive internationally in terms of operation standards and
market expansion.” President and CEO of FosunPharma said.
For more details, please click the link below:

https://www.fosunpharma.com/en/news/news-details-3785.html

IT Shades
Engage & Enable
Medtronic Reports First Quarter Financial Results
Key Financial Highlights

2
• Revenue of $7.5 Billion Increased 1.5% Reported; Increased
3.5% Constant Currency
• GAAP Diluted EPS of $0.64; Non-GAAP Diluted EPS of
$1.26
• Company Raises FY20 EPS Guidance by 10 Cents
“Medtronic had a solid first quarter, delivering revenue
growth, operating margin expansion, and adjusted EPS
growth all ahead of expectations,” saidMedtronic
chairman and chief executive officer. “It’s a good start to
our fiscal year.”

http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-reports-first-quarter-financial-results-3

IT Shades
Engage & Enable
Amgen to Acquire Otezla® For $13.4 Billion In Cash,

Or Approximately $11.2 Billion Net Of Anticipated
Description 3
Amgen announced that it has entered into an agreement with
Celgene Corporation in connection with its previously
announced merger with Bristol-Myers Squibb Company to
acquire worldwide rights to Otezla® (apremilast), the only oral,
non-biologic treatment for psoriasis and psoriatic arthritis, and
certain related assets and liabilities, for $13.4 billion in cash, or
approximately $11.2 billion, net of the present value of $2.2
billion in anticipated future cash tax benefits.
"The acquisition of Otezla offers a unique opportunity for Amgen to provide
patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits
squarely within our portfolio and complements our Enbrel® and AMGEVITA®
brands," said Chairman and chief executive officer at Amgen. "We will take
advantage of our 20 years of experience in inflammatory disease to realize the
full global potential of Otezla as an affordable option for patients with these
serious, chronic inflammatory conditions."

https://www.amgen.com/media/news-releases/2019/08/amgen-to-acquire-otezla-for-134-billion-in-cash-or-approximately-112-billion-net-of-anticipated-future-cash-tax-benefits/

IT Shades
Engage & Enable
Stryker announces definitive agreement to acquire

Mobius Imaging & Cardan Robotics
Description
4
Stryker announced a definitive agreement to acquire Mobius Imaging, LLC, a leader in
point-of-care imaging technology, and its sister company, GYS Tech, LLC (DBA Cardan
Robotics), in an all cash transaction of approximately $370 million upfront and up to $130 million
of contingent payments associated with development and commercial milestones. The acquisition
provides Stryker’s Spine division with immediate entry into the intra-operative imaging segment
and aligns with Stryker’s implant and navigation offerings. Mobius Imaging, founded in 2008, is
focused on integrating advanced imaging technologies into medical workflow, which can enhance
a clinician’s ability to obtain high-quality images. Its AiroTruCT scanner is a best-in-class mobile,
real-time, diagnostic-quality CT imaging system. Cardan Robotics, founded in 2015, is working to
develop innovative robotics and navigation technology systems for surgical and interventional
radiology procedures.
"This acquisition brings expertise in advanced imaging and robotics as well as a
robust product pipeline that add to Stryker’s portfolio and will allow the Spine
division to provide more complete procedural solutions, including sales, service,
and support," said Stryker’s Group President, Orthopaedics and Spine. "We look
forward to working together to advance Stryker’s mission to make healthcare
better and accelerate our pursuit of category leadership in Neurotechnology,
Orthopaedics, and Spine."

https://investors.stryker.com/press-releases/news-details/2019/Stryker-announces-definitive-agreement-to-acquire-Mobius-Imaging--Cardan-Robotics/default.aspx

IT Shades
Engage & Enable
Boston Scientific Closes Acquisition of BTG plc.
Description
5
Boston Scientific Corporation announced the completion of its acquisition of BTG
plc. pursuant to the previously announced scheme of arrangement. BTG develops and
commercializes products used in minimally-invasive procedures targeting cancer and
vascular diseases, as well as specialty pharmaceuticals. BTG has three key
businesses, the largest of which is its highly-differentiated Interventional Medicine
portfolio that encompasses interventional oncology therapeutic technologies for
patients with liver and kidney cancers, as well as a vascular portfolio for treatment of
deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial
venous disease.
"The addition of the BTG Interventional Medicine portfolio reinforces our
category leadership strategy and enables us to offer best-in-class technologies,
unparalleled clinical evidence and a strengthened commercial infrastructure to
support physicians treating some of the most challenging diseases impacting
patient health around the world," said Chairman and chief executive officer,
Boston Scientific. "Leveraging the employee talent and clinical and commercial
expertise of these two high-performing organizations will generate continued
innovation and access so that we may advance patient care in ways that neither
company could do alone."
https://news.bostonscientific.com/2019-08-19-Boston-Scientific-Closes-Acquisition-of-BTG-plc

IT Shades
Engage & Enable
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine

treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
Description
6
H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals announced a definitive
agreement for Lundbeck to acquire Alder. Under the terms of the agreement,
Lundbeck will commence a tender offer for all outstanding shares of Alder, whereby
Alder stockholders will be offered an upfront payment for USD 18.00 per share in
cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them
to an additional USD 2.00 per share upon approval of eptinezumab by the European
Medicines Agency (EMA), representing a total potential consideration of USD 20.00
per share. The transaction is valued at up to USD 1.95 billion (approximately DKK
13 billion) net of cash, on a fully diluted basis.
President and CEO of Lundbeck, commented “Alder is an excellent strategic fit for
Lundbeck’s focused expertise in brain diseases and organizational capabilities. This
transaction flows from our strategic intent to Expand and Invest to Grow. Migraine
prevention is an attractive indication for us that leverages our specialized commercial
expertise in delivering medicines for brain diseases. We expect the global launch of
eptinezumab for the preventive treatment of migraine, as well as the further potential
development of the product in additional indications, to accelerate Lundbeck’s growth
in the coming years.”

https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-acquire-alder-biopharmaceuticals-company-committed

IT Shades
Engage & Enable
Solution Updates
Healthcare Industry

IT Shades
Engage & Enable
Regeneron Debuts on Prestigious Dow Jones Sustainability

World Index of Most Sustainable Companies
Solution Descriptio n
7
Regeneron Pharmaceuticals, Inc. announced that the

company was added to the Dow Jones Sustainability
World Index (DJSI World) for the first time. Regeneron is
one of only four companies in the biotechnology sector to
be included on the DJSI World list. DJSI World is a
leading global index comprised of corporate leaders in
environmental, social and governance (ESG) practices,
which recognizes the top 10 percent most sustainable
companies in each industry.DJSI World is considered the
gold standard for measuring corporate ESG practices. It is
published by S&P Dow Jones Indices, one of the world's
leading index providers, together with RobecoSAM,
which specializes in ESG data and benchmarking. This
year, more than 4,500 global companies were invited to
participate in the evaluation process.

https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-debuts-prestigious-dow-jones-sustainability-world

IT Shades
Engage & Enable
Roche receives FDA clearance for cobas pro integrated solutions

designed to help labs deliver faster results to patients
8
Roche Diagnostics announced that the US Food and Drug
Administration (FDA) has cleared its cobas pro® integrated
solutions, a new generation of Serum Work Area (clinical
chemistry and immunochemistry) laboratory solution, designed
to optimize lab operations. With the cobas pro integrated
solutions, laboratories are now able to run tests faster on less
equipment, automate manual tasks and deliver results more
quickly to aid in treatment decisions. Diagnostic laboratories
are a critical component of the global healthcare system with in
vitro diagnostics influencing up to 70% of all clinical decisions
while accounting for only about 2% of total healthcare
spending.1,2 Together, medical and lab professionals play a key
role in delivering optimal patient care, yet they face increasing
pressure to manage a growing number of samples, while
delivering quality results faster and rising profitability.

https://www.roche.com/media/releases/med-cor-2019-09-16.htm

IT Shades
Engage & Enable
Medtronic Introduces Envision™ Pro Continuous Glucose

Monitoring (CGM) System in Europe
9
Medtronic plc, the global leader in medical technology, services and solutions,
announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system
— a fully disposable, zero calibration professional CGM system — has
obtained CE (ConformitéEuropéenne) Mark approval. Medtronic will begin
commercial release in Europe and the Middle East this fall, subject to local
regulatory requirements1. This new technology will empower healthcare
professionals and their patients with either type 1 and type 2 diabetes to see
accurate glucose levels and trends over time to develop more optimal diabetes
therapy plans.The Envision Pro system was designed with ease of use as a top
priority. For instance, patients no longer need to calibrate the CGM through
fingersticks. Also, there is no need to return the sensor or recorder to their
physician, as both pieces are now fully disposable. The recorder communicates
wirelessly with the patient’s smartphone allowing automatic data uploading so
that the healthcare provider obtains the data seamlessly and can run reports
remotely without additional in-office visits.

http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-introduces-envisiontm-pro-continuous-glucose

IT Shades
Engage & Enable
European Commission approves Roche’s Tecentriq in combination with Abraxane

for people with PD-L1-positive, metastatic triple-negative breast cancer
10
Roche announced that the European Commission has approved Tecentriq® (atezolizumab)
plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable
suspension (albumin-bound); nab-paclitaxel]) for the treatment of adult patients with
unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose
tumours have PD-L1 expression (≥1%) and who have not received prior chemotherapy for
metastatic disease. Roche’s VENTANA PD-L1 (SP142) Assay is now CE marked and
commercially available in the European Union as an aid for identifying patients with
TNBC eligible for treatment with the Tecentriq combination.This approval is based on the
results from the Phase III IMpassion130 study. Progression-free survival (PFS) results
demonstrated a statistically significant benefit for Tecentriq in combination with
nab-paclitaxel and showed that Tecentriq plus nab-paclitaxel significantly reduced the risk
of disease worsening or death (PFS) by 38% compared with nab-paclitaxel alone (median
PFS=7.5 vs 5 months; hazard ratio [HR]=0.62, 95% CI: 0.49-0.78, p<0.0001) in people
who were tested positive for PD-L1 expression on tumour-infiltrating immune cells. At the
second interim analysis, Tecentriq and nab-paclitaxel showed a clinically meaningful
overall survival (OS) improvement of seven months vs placebo and nab-paclitaxel in the
PD-L1-positive population (median OS=25.0 vs 18.0 months; HR=0.71, 95% CI: 0.54
–0.93). OS results in the PD-L1-positive population were not formally tested due to the
hierarchical design of the study as statistical significance was not met for OS in the
intention-to-treat (ITT) population (median OS=21.0 vs 18.7 months; HR=0.86, 95% CI:
0.72–1.02, p=0.078).


IT Shades
Engage & Enable
European Commission approves Roche’s new Tecentriq-based combination therapy

as an initial treatment for most common form of advanced lung cancer
11
Roche announced that the European Commission has approved and granted
marketing authorisation for Tecentriq® (atezolizumab) in combination with
chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel;
nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic
non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant
or ALK-positive NSCLC.This approval is based on results from the Phase III
IMpower130 study, which demonstrated that the Tecentriq combination therapy
helped people live significantly longer, compared with chemotherapy alone (median
overall survival [OS]=18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI:
0.64–0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) population.1 The
Tecentriq-based combination also significantly reduced the risk of disease worsening
or death (progression-free survival [PFS]) compared with chemotherapy alone
(median PFS=7.0 versus 5.5 months; HR=0.64; 95% CI: 0.54–0.77; p<0.0001) in the
ITT-WT population.1 The safety profile of the Tecentriq combination therapy was
consistent with that observed in previous studies.Lung cancer is the leading cause of
cancer death globally, and each year 1.76 million people die as a result of the disease,
which translates into more than 4,800 deaths worldwide every day.2 NSCLC is the
most prevalent type of lung cancer, accounting for around 85% of all cases.3


IT Shades
Engage & Enable
Henry Schein Medical Expands SolutionsHub Portfolio

with CueSquaredMobilePay™
12
Henry Schein Medical, the U.S. medical business of Henry Schein,

Inc., announced the expansion of its SolutionsHub with
CueSquaredMobilePay™, a new platform that augments the collection
efforts of patient self-pay balances, allowing patients to access and pay
their bills anywhere, at any time. CueSquaredMobilePayincreases
patient revenue, accelerates payments, and reduces costs to
collect.CueSquaredMobilePaystrengthens existing self-pay collection
strategies by transforming patient statement data into SMS text-based
statements. This enables patients to easily make payments within hours
of receiving MobilePay statements. With MobilePay, patients securely
receive text statements and can make payments without having to log
into a portal or download an application. Following a medical visit,
patients will receive a text notification advising that a payment is due,
and once received, the patient can view their payment history,
statement details, and pay with one click.

http://investor.henryschein.com/news-releases/news-release-details/henry-schein-medical-expands-solutionshub-portfolio-cuesquared

IT Shades
Engage & Enable
Impella® SmartAssist Platform Launches at ESC,

Designed to Further Improve Patient Outcomes
13
Abiomed announces that the Impella CP® with SmartAssist

technology, which is designed to improve patient outcomes with
advanced algorithms and simplified patient management, will be
commercially available in Europe beginning at the European Society
of Cardiology (ESC) Congress 2019 through a controlled roll out
process at select sites. The majority of Impella CP heart pumps in
Europe will be transitioned to SmartAssist over the next 12
months.The new Impella CP heart pump features a fiber optic sensor,
optimally positioned to measure the placement signal in the aorta,
identify pump placement and enable repositioning without the use of
imaging. The advanced sensors also enable the calculation and display
of additional physiological data on the Automated Impella Controller.
These advances to the Impella forward-flow heart pump technologies
and software are designed to improve ease-of-use and patient
management to improve both survival and heart recovery:

http://investors.abiomed.com/news-releases/news-release-details/impellar-smartassist-platform-launches-esc-designed-further

IT Shades
Engage & Enable
Rewards & Recognition Updates

Healthcare Industry

IT Shades
Engage & Enable
Roche ranked as one of the most sustainable healthcare companies in the

Dow Jones Sustainability Indices for the eleventh year running
R&R Description
14
Roche has again been recognised as one of the most sustainable
companies in the Pharmaceuticals index of the Dow Jones
Sustainability Indices (DJSI). This is based on an in-depth analysis of
economic, social and environmental performance. The DJSI family of
indices serves as a benchmark for investors who integrate
sustainability considerations into their portfolios. Roche has
maintained its leadership through its excellent sustainability strategy,
which is fully embedded in the company’s business and culture.For
Roche, it is a priority to ensure that medicines and diagnostics reach
the people who need them. This is why, the company is committed to
constantly identifying and eliminating barriers to access to healthcare.
For example, Roche undertook an evaluation of the supply chain in
Kenya, Ethiopia, Sudan, Côte d'Ivoire, Nigeria, Ghana to develop new
lean supply chain models. This included removing complexity,
improving quality and moving towards directly supplying governments
and points of care in the countries. Reorganising the supply chain
reduced lead time from Switzerland to local warehouses significantly,
in the case of Kenya from 90 to 21 days.

https://www.roche.com/media/releases/med-cor-2019-09-16b.htm

IT Shades
Engage & Enable
Biogen Ranked #1 Biotechnology Company on

Dow Jones Sustainability World Index
R&R Description
15
Biogen Inc. announced that it has been ranked the #1
biotechnology company on the Dow Jones Sustainability
World Index (DJSI World) for the fourth time, after being
the first U.S.-based biotech company to ever make the list
in 2013. DJSI World recognizes the top 10 percent of
companies in the S&P Global Broad Market Index for
their long-term commitment to environmental, social and
governance performance. Of the 318 companies named to
DJSI World, Biogen led the biotechnology industry, with
top scoring in multiple areas, including addressing cost
burden, marketing practices, environmental reporting,
policies and management systems, human rights, climate
strategy and human capital development.

http://investors.biogen.com/news-releases/news-release-details/biogen-ranked-1-biotechnology-company-dow-jones-sustainability

IT Shades
Engage & Enable
Good Neighbor Pharmacy Receives "Highest in Customer Satisfaction

with Chain Drug Store Pharmacies” from J.D. Power
R&R Description
16
Good Neighbor Pharmacy – a national independent pharmacy network
offered through AmerisourceBergen – announced that it has been
ranked “Highest in Customer Satisfaction with Chain Drug Store
Pharmacies” in the J.D. Power 2019 U.S.Pharmacy Study. This marks
the eighth time that Good Neighbor Pharmacy has earned the
achievement in the last 10 years.This year, Good Neighbor Pharmacy
ranked the highest in overall satisfaction among chain drug store
pharmacies. Good Neighbor Pharmacy received a score of 914 while
the average was 842. Additionally, Good Neighbor Pharmacy ranked
highest in five factors: Prescription Ordering and Filling Process;
Pharmacist; Non-Pharmacist Staff; Cost Competitiveness; and
Store.The customer service recognition follows AmerisourceBergen’s
recent unveiling of new tools that help pharmacies connect with
customers in new and meaningful ways. These tools include
medication adherence support, a market analysis report and expanded
digital marketing services. The resources offer pharmacists solutions
that fit within their existing workflows and empower them to establish
strong relationships with their customers.

https://www.amerisourcebergen.com/newsroom/press-releases/2019-good-neighbor-pharmacy-receives-highest-in-customer-satisfaction

IT Shades
Engage & Enable
Stryker honored by Women’s Forum for work toward

gender parity in the boardroom
R&R Description
17
Stryker will receive an award from the Women’s Forum
of New York in recognition of gender parity in the
boardroom at their biennial Breakfast of Corporate
Champions this November. Chairman and CEO, has
doubled the number of women on Stryker’s board of
directors from two to four during his tenure with the
company, even increasing the number of positions from
nine to ten when he found an ideal female board member.
CEO commitment to diversity stems from a background
in different industries, countries and cultures which has
instilled in him a deep understanding of the value
diversity can bring to an organization.

https://www.stryker.com/us/en/about/news/2019/stryker-honored-by-women-s-forum-for-work-toward-gender-parity-i.html

IT Shades
Engage & Enable
Baxter Named to 2019 Dow Jones Sustainability Indices
R&R Description
18
Baxter International Inc., a leading global medical products company,
announced it has again been named to the Dow Jones Sustainability Indices
(DJSI)—the DJSI World and DJSI North America—designations Baxter has
received annually since the indices were launched in 1999 and 2005,
respectively. Demonstrating a continued focus on its sustainability efforts,
Baxter scored in the top five percent of companies assessed within the health
care equipment and supplies industry, with leading performance in
environmental reporting, strategy to improve access to drugs or products,
marketing practices and policy influence.Baxter’s corporate responsibility
strategy continues to drive more sustainable operations, enhance product
quality, build healthy communities, foster a strong work environment and
improve access to healthcare. In June, the company published its 2018
Corporate Responsibility Report, which highlights accelerated progress toward
a number of Baxter’s 2020 Corporate Responsibility priorities and goals.

https://www.baxter.com/baxter-newsroom/baxter-named-2019-dow-jones-sustainability-indices

IT Shades
Engage & Enable
Shanghai Pharmaceuticals ranked 11th in the "Top 20 Companies in 2019 Shanghai"

and ranked 4th in the "Top 100 Manufacturing Enterprises in 2019"
R&R Description
19
The 2019 Shanghai Top 100 Enterprises Conference, jointly organized
by the Shanghai Enterprise Confederation, Shanghai Entrepreneur
Association, Shanghai Economic Association and Jiefang Daily, was
held on the afternoon of August 19. At the meeting, a list of 2019
Shanghai Top 100 Enterprises and Top 100 Shanghai Manufacturing
Enterprises was released. Shanghai Pharmaceutical ranked 11th in the
"Top 20 Companies in 2019 Shanghai", up 3 places from last year;
ranked 4th in the "Top 100 Manufacturing Enterprises in 2019", an
increase of 1 year compared with last year, and continued to maintain a
good momentum of rising year by year. Vice president of Shanghai
Pharmaceuticals and director of the Manufacturing Management
Center attended the conference on behalf of the company and received
the award.

http://www.sphchina.com/news_center/news_detail.html?id=415

IT Shades
Engage & Enable
Shanghai Pharmaceuticals is ranked among the top ten

in China's top 100 pharmaceutical industry
R&R Description
20
National Pharmaceutical Industry Information Annual Conference hosted by China
Medical Industry Information Center was grandly opened in Lianyungang. The
conference released the "Top 20 Chinese Pharmaceutical Industry Enterprises in
2018" and other high-profile enterprises. A list of industry trends. Deputy secretary of
the Party Committee of Shanghai Pharmaceutical Group and vice president of
Shanghai Pharmaceuticals received the top 100 awards on behalf of the company.
In this selection, Shanghai Pharmaceutical Group continued to rank sixth in the “Top
100 Enterprises in China's Pharmaceutical Industry in 2018” and won the “Top 25
Best Industrial Enterprises in China's Pharmaceutical R&D Product Line in 2019”.
Its subsidiary, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd., was
awarded the “Top 10 Most Growing Enterprises in China's Pharmaceutical Industry
in 2019”; the joint venture Shanghai Hehuang Pharmaceutical Co., Ltd. was awarded
“The Most Investing Value Enterprise in China's Pharmaceutical Industry in 2018
(Non- Listed in the top 10".


IT Shades
Engage & Enable
The top 500 Chinese companies were released, and the

Shanghai pharmaceutical rankings rose by 7
R&R Description
21
At the 2019 China Top 500 Enterprises Summit Forum, the China Enterprise
Confederation and the China Entrepreneur Association released the list of “Top 500
Chinese Enterprises” to the public for the 18th time. The top 500 is on the list.
Shanghai Pharmaceutical ranked 122nd among the “Top 500 Chinese Enterprises”
with its operating income of 159,084,400,000 yuan in 2018, up 7 places from last
year; ranked 43rd among the “Top 500 Chinese Manufacturing Enterprises”, up 4
places compared with last year. And continue to maintain the industry's leading
position. It is reported that the operating income of the top 500 Chinese enterprises in
2019 continues to grow. In 2019, the top 500 Chinese enterprises achieved a total
operating income of 79.10 trillion yuan, an increase of 11.14% over the previous
year's top 500. The top 500 enterprises have made outstanding contributions to GDP.
In recent years, the contrast between operating income and GDP has risen steadily.
The entry threshold has increased for 17 consecutive years, and the threshold for the
top 50 Chinese companies in 2019 has increased to 32.325 billion yuan. The total
assets maintained a medium-speed growth, and the net assets and the net assets
attributable to the parent company grew faster than the total assets. In addition, in
general, the business performance of the top 500 manufacturing groups has
rebounded significantly, and the growth rate of net profit has remained at a high
level, and is constantly moving toward the mid-end of the industrial chain.


IT Shades
Engage & Enable
Regeneron Debuts on Prestigious Dow Jones Sustainability

World Index of Most Sustainable Companies
R&R Description
22
Regeneron Pharmaceuticals, Inc. announced that the company
was added to the Dow Jones Sustainability World Index (DJSI
World) for the first time. Regeneron is one of only four
companies in the biotechnology sector to be included on the
DJSI World list. DJSI World is a leading global index
comprised of corporate leaders in environmental, social and
governance (ESG) practices, which recognizes the top 10
percent most sustainable companies in each industry.DJSI
World is considered the gold standard for measuring corporate
ESG practices. It is published by S&P Dow Jones Indices, one
of the world's leading index providers, together with
RobecoSAM, which specializes in ESG data and
benchmarking. This year, more than 4,500 global companies
were invited to participate in the evaluation process.

https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-debuts-prestigious-dow-jones-sustainability-world

IT Shades
Engage & Enable
Partnership Ecosystem Updates

Healthcare Industry

IT Shades
Engage & Enable
Google Photos and CVS Pharmacy Team Up to Offer Same-Day

Printing at More Than 7,400 Locations Nationwide
Description 23
CVS Pharmacy, the retail division of CVS Health announced a collaboration
with Google Photos on their new same-day, print-to-store experience.
Consumers can now order high-quality 4x6 prints directly from Google Photos
for same-day pick up at more than 7,400 CVS Pharmacy locations nationwide.
The printing service for CVS Pharmacy, powered by Kodak Moments' vast
global retail network and enhanced software technology, begins rolling out
across the country and will be broadly available by this October. Consumers are
increasingly looking for convenient and easy ways to print out their digital
photos, according to a 2018 Kodak Moments U.S. Attitudes and Usage Study
conducted by Keypoint Intelligence InfoTrends, 64% of US consumers print
photos and over a third plan to print more in the future. Originally launched in
2015, Google Photos serves as the home for photos and videos, helping people
save, organize and share their photos and videos. Accessible via iOS or Android
as well as through Google Photos on the web, the same-day printing service is
made possible through participation in the Kodak Moments Prints partner API
program, so consumers can effortlessly bring their digital snapshots to life at
participating CVS stores throughout the U.S.

https://cvshealth.com/newsroom/press-releases/google-photos-and-cvs-pharmacy-team-offer-same-day-printing-more-7400

IT Shades
Engage & Enable
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery
technologies to help change the way diabetes is managed
Description 24
Sanofi and Abbott are partnering to integrate glucose sensing and insulin
delivery technologies that would help to further simplify how people with
diabetes manage their condition. The two companies will take an
innovative approach to connected care by developing tools that combine
the revolutionary FreeStyle Libre technology with insulin dosing
information for future smart pens, insulin titration apps and cloud
software.The non-exclusive collaboration will initially enable data sharing,
at the consent of the user, between Abbott’s FreeStyle Libre mobile app
and cloud software and Sanofi’s connected insulin pens, apps and cloud
software that are currently in development. This data sharing will enable
both people with diabetes and their doctors to make better informed
treatment decisions around medication, nutrition and lifestyle.Sanofi is
currently working to provide connected pens, apps and cloud software that
will be compatible with the FreeStyle Libre system and its compatible
digital health tools. The two companies aim to bring this to people with
diabetes within the next few years, pending local regulatory approvals.

https://www.sanofi.com/en/media-room/press-releases/2019/2019-09-16-07-00-00

IT Shades
Engage & Enable
Medtronic and Novo Nordisk Enter Agreement to Provide

Integrated Digital Solutions for People with Diabetes
Description 25
Medtronic plc, and Novo Nordisk A/S announced a collaboration that will develop
solutions to integrate insulin dosing data from future Novo Nordisk smart insulin
pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as
the Guardian™ Connect system. People with diabetes spend an average of one hour a
day on self-care, amounting to a full two years devoted exclusively to their disease
over their lifetime.1,2This new, non-exclusive collaboration reflects both
companies′commitment to making diabetes management easier by integrating key
health technologies.By integrating glucose monitoring and insulin dosing data,
people with diabetes and their healthcare professionals and caregivers (with
permission from the person with diabetes) will be able to automatically track these
two important items in a single place, giving people living with diabetes one less
thing to think about in the daily management of their condition. Further, being able to
view both glucose and insulin data together can facilitate more productive
conversations between people and their doctors, enabling more informed decisions
on how to better manage glucose levels and increase Time in Range (TIR) - the
percentage of time people with diabetes spend in the optimal glycaemic range of
70-180 mg/dL.3

http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-and-novo-nordisk-enter-agreement-provide-integrated

IT Shades
Engage & Enable
Memorial Healthcare System joins Aetna’s Medicare

Advantage network in Broward County
Description 26
Aetna, a CVS Health company, has signed an agreement to add
Memorial Healthcare System to its Medicare network, effective
immediately. Under this new agreement, members of Aetna’s
Medicare Advantage plan can now receive covered services, at
in-network rates, from Memorial’s six hospitals, two urgent
care facilities and five ambulatory surgical centers in Broward
County.Memorial Healthcare System is proud to be Moving
Health Forward as one of the largest public healthcare systems
in the US and a national leader in quality care and patient
satisfaction. It has been ranked on Modern Healthcare
magazine’s list of Best Places to Work in Healthcare.

https://news.aetna.com/news-releases/2019/08/memorial-healthcare-system-joins-aetnas-medicare-advantage-network-in-broward-county/

IT Shades
Engage & Enable
Blue Cross and Blue Shield of Minnesota and Minnesota

Oncology Announce Five-Year Collaboration
Description 27
Blue Cross and Blue Shield of Minnesota and Minnesota Oncology, a practice in The
US Oncology Network, announced a five-year agreement that will change the way
cancer care is paid for and managed in order to deliver optimal health outcomes at
lower costs.This collaboration, which takes effect September 1, 2019, will make Blue
Cross and Minnesota Oncology jointly accountable for the overall cost of cancer care
provided to Blue Cross members through a value-based risk arrangement. The terms
of the arrangement are based on the principle that effective outcomes for patients are
determined by the quality of care provided – not the quantity.With an enhanced focus
on patient-centric healthcare, clinical staff at Minnesota Oncology will offer care
coordination services on an individualized basis for Blue Cross members. This
approach will help to ensure that the comprehensive care model already in place
consistently delivers the best possible outcomes by providing appropriate, medically
necessary care at the right time and place.The five-year collaboration will include an
agreed-upon set of quality metrics based on the latest scientific research and proven
clinical guidelines. Minnesota Oncology will be responsible for ensuring continued
alignment with evidence-based best practices and, as a result, will no longer be
required to secure prior authorization from Blue Cross for coverage of selected
services that are typically associated with high rates of overutilization.

https://www.mckesson.com/about-mckesson/newsroom/press-releases/2019/blue-cross-and-minnesota-oncology-collaboration/

IT Shades
Engage & Enable
McKesson and TrakCel Launch Innovative Collaboration to

Support Commercialization of Cell and Gene Therapies
Description 28
McKesson, a leading provider of third-party logistic (3PL) services, patient access support
and specialty pharmacy solutions, and TrakCel, the software developer for cell and gene
therapy supply chain tracking and orchestration systems, announce a collaboration to
support cell and gene therapy late-stage developers. The collaboration will integrate both
companies’ supply chain tracking and patient access services to enable a more efficient path
for the industry to develop the next-generation of commercial therapies. Combining
TrakCel’s data tracking and personalized medicine orchestration software system with
McKesson’s existing high-touch patient platform, as well as both companies’ expertise and
support, will provide an end-to-end solution for the cell and gene therapy industry to
manage the entire therapeutic supply chain. McKesson and TrakCel will begin by
developing an initial solution design. The combined solutions will then be offered to
individual clients that would specifically benefit from this combination. The blend of these
product suites is specifically designed for the increasing number of developers approaching
the commercial launch of cell and gene therapies. The integrated platform enables the
scale-up of products towards market delivery. This includes automatic scheduling of
product-specific workflows across multiple supply chain partners and care team members,
and validated chain-of-identity tracking to guarantee correct drug product delivery. These
capabilities ensure that the patient receives the correct, uncompromised treatment at the
right time.

https://www.mckesson.com/about-mckesson/newsroom/press-releases/2019/mckesson-and-trakcel-launch-collaboration/

IT Shades
Engage & Enable
Quest Diagnostics and hc1 Collaborate to Optimize Enterprise-wide

Laboratory Testing for Health Systems
Description 29
Quest Diagnostics, the world's leading provider of diagnostic

information services, and hc1, the bioinformatics leader in
precision testing, today unveiled Quest® Lab Stewardship™
powered by hc1®, an innovative new service that employs
machine learning to harmonize laboratory testing across health
systems in order to help optimize laboratory test utilization.
Quest Lab Stewardship is the result of a strategic collaboration
between Quest and hc1 focused on improving costs and clinical
impact of lab testing, in- and out- of hospital settings.In recent
years, health systems and hospitals have implemented "test
utilization" programs to identify patterns in lab ordering trends.
However, these programs often require time-consuming manual
uploads of data or use platforms that cannot pull from disparate
enterprise systems or provide real-time test ordering guidance.

http://newsroom.questdiagnostics.com/2019-09-12-Quest-Diagnostics-and-hc1-Collaborate-to-Optimize-Enterprise-wide-Laboratory-Testing-for-Health-Systems

IT Shades
Engage & Enable
GPHL and Kangmei Pharmaceutical signed a strategic

cooperation to jointly revitalize Da Nang
Description 30
Guangzhou Pharmaceutical Group Co., Ltd. and Kangmei Pharmaceutical Co.,
Ltd. held a signing ceremony for the strategic cooperation agreement at the
headquarters of Guangzhou Pharmaceutical. The two parties will integrate the
advantageous resources in the field of Chinese medicine and give full play to
their respective advantages in the management of Chinese herbal medicine
supply chain. Cooperation in product channel services and other areas to jointly
help "revitalize Da Nan medicine." During the period, the two sides conducted
in-depth exchanges on the prospects for future cooperation. Li Chuyuan said
that Kangmei Pharmaceutical adheres to the remarkable achievements in the
inheritance and innovation of Chinese medicine culture, successfully builds a
comprehensive industrial chain resource integration platform, and has a flexible
operation system to realize the national distribution of “smart +” big health
industry, leading the industry, and is a private enterprise in the Chinese
medicine industry. Representatives, models. As a state-owned enterprise, GPHL
maintains its own unique characteristics in the development of the big health
industry. This is in line with the development of Kangmei Pharmaceutical's
main business. There are still many space for further cooperation in the field of
big health industry.

http://www.kangmei.com.cn/index.php?m=content&c=index&a=show&catid=305&id=3533

IT Shades
Engage & Enable
Eisai Enters Into Business Alliance with CogstateFor Exclusive Development And Commercialization
Of A Digital Tool For Self-Assessment Of Cognitive Function In Japan
Description 31
Eisai Co., Ltd. announced that it has entered into a business alliance
agreement for exclusive development and commercialization of a
cognitive function test - Cogstate Brief Battery (CBB) - developed by
Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive
function. The CBB consists of four tests, each measuring different
cognitive domains: psychomotor function, attention, working memory,
and learning, and it has been developed and already in use as a digital
tool for self-assessment of cognitive function overseas, including the
United States. Eisai will aim to raise awareness of cognitive function
by developing and making widely available the CBB in Japan jointly
with Cogstate as a simpler digital tool for self-assessment of cognitive
function, which can be used at various locations such as at home and
community events. With this tool, it is expected to have opportunities
to review lifestyle and to consult with specialists and primary care
physicians by objectively checking the changes in cognitive function.
It is important to note that this tool is not an alternative for medical
examination and diagnosis by qualified medical professionals.

https://www.eisai.com/news/2019/news201963.html

IT Shades
Engage & Enable
Royal HaskoningDHV, CEAD and DSM design first

lightweight 3D printed bridge using FRP
Description 32
Royal HaskoningDHV, CEAD and DSM announced that
they have designed the first lightweight 3D printed FRP
pedestrian bridge prototype using a composite material. It
consists of a glass filled thermoplastic PET (Arnite®) and
is combined with continuous glass fibers which are added
in the 3D printing process. This unique combination
offers high strength with extreme versatility and
sustainability.Together, the three companies are leading a
revolution in bridge construction and design. To build a
3D printed bridge Royal HaskoningDHV, an international
engineering and project management consultancy,
partnered with DSM, a global science-based company in
nutrition, health and sustainable living and pioneer in 3D
printing materials, and CEAD, supplier of 3D printing
equipment on the frontier of large-scale composite
additive manufacturing.
https://www.dsm.com/corporate/news/news-archive/2019/2019-09-03-royal-haskoningdhv-cead-and-dsm-design-first-lightweight-3d-printed-bridge-using-frp.html

IT Shades
Engage & Enable
Allergan and Molecular Partners Announce Acceptance of U.S.

FDA Biologics License Application and Validation of EMA
Description 33
Allergan plc a leading global pharmaceutical company with a
heritage of more than 70 years in eye care, and Molecular
Partners a clinical-stage biotechnology company developing a
new class of drugs known as DARPin® platform, announced
that the U.S. Food and Drug Administration (FDA) has
accepted a Biologics License Application (BLA) and the
European Medicines Agency (EMA) has validated a Marketing
Authorisation Application (MAA) for Abicipar pegol, a novel,
investigational DARPin® therapy, in patients with neovascular
(wet) age-related macular degeneration (nAMD). The FDA is
expected to take action on the BLA mid-2020. A decision from
the European Commission is expected in the second half of
2020.The BLA and MAA filings are based on data from two
Phase 3 trials, CEDAR and SEQUOIA, which supported the
non-inferior efficacy of the Abicipar quarterly dosing regimen
to maintain vision gains with more than 50 percent fewer
injections versus ranibizumab (13 vs. 6) dosed monthly in the
first year.

https://www.allergan.com/news/news/thomson-reuters/allergan-and-molecular-partners-announce-acceptanc

IT Shades
Engage & Enable
Miscellaneous Updates
Healthcare Industry

IT Shades
Engage & Enable
Covance Unveils New R&D Center in Shanghai
Description
34
LabCorp® , a leading global life sciences company that is
deeply integrated in guiding patient care, announced that
its Covance Drug Development business celebrated the
opening of its new R&D Center in Shanghai, China,
which is now its largest facility in the Asia Pacific region.
The opening ceremony was attended by Chao Yang, vice
chairman of the Shanghai Municipal Commission of
Commerce; Feng Huang, chairman of the Shanghai
Association of Foreign Investment; John Ratliff, CEO,
Covance; and Honggang Bi, Ph.D., corporate vice
president of Covance and general manager, China, as well
as biopharmaceutical and biotech industry leaders,
clinical research key opinion leaders, research partners
and local dignitaries.

https://ir.labcorp.com/news-releases/news-release-details/covance-unveils-new-rd-center-shanghai

IT Shades
Engage & Enable
Illumina Recommends Stockholders Reject Mini-Tender

Offer by TRC Capital Corporation
Description 35
Illumina, Inc. has been notified of an unsolicited
“mini-tender offer” by TRC Capital Corporation (“TRC”)
to purchase up to 500,000 shares of Illumina common
stock at a price of $268.80 per share in cash. TRC’s offer
is subject to a number of conditions, including TRC’s
ability to obtain sufficient financing. By its terms, TRC’s
offer will expire at 12:01 a.m., New York City time, on
Thursday, October 3, 2019, but TRC may extend the offer,
or terminate it, before the expiration date. Illumina is not
affiliated or associated in any way with TRC, its offer or
the offer documentation. Illumina recommends that
stockholders not tender their shares in response to TRC's
unsolicited offer because, among other things, it deprives
stockholders who tender their Illumina shares of the
potential opportunity to realize greater long-term value in
their investment.
https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=3a22851b-22fa-42db-9a23-8e8a4624abb3

IT Shades
Engage & Enable
Follow us on social media by clickling below:
http://www.facebook.com/ITShades-1184984251622300/
http://www.facebook.com/ITShades-1184984251622300/ http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 / w w w . y o u t u b e . c o m / c h a n n e l / U C m f V P K O Q 2 I M E Q Q W 2 5 P 4 - I h Q
http://www.facebook.com/ITShades-1184984251622300/ http://www.instagram.com/itshades1 http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 /

w
w
w
w
w
w
.
.
y
y
o
o
u
u
t
t
u
u
b
b
e
e
.
.
c
c
o
o
m
m
/
/
c
c
h
h
a
a
n
n
n
n
e
e
l
l
/
/
U
U
C
C
m
m
f
f
V
V
P
P
K
K
O
O
Q
Q
2
2
I
I
M
M
E
E
Q
Q
Q
Q
W
W
2
2
5
5
P
P
4
4
-
-
I
I
h
h
Q
Q

http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 /
w
w
w
w
w
w
w
w
w
.
.
.
y
y
y
o
o
o
u
u
u
t
t
t
u
u
u
b
b
b
e
e
e
.
.
.
c
c
c
o
o
o
m
m
m
/
/
/
c
c
c
h
h
h
a
a
a
n
n
n
n
n
n
e
e
e
l
l
l
/
/
/
U
U
U
C
C
C
m
m
m
f
f
f
V
V
V
P
P
P
K
K
K
O
O
O
Q
Q
Q
2
2
2
I
I
I
M
M
M
E
E
E
Q
Q
Q
Q
Q
Q
W
W
W
2
2
2
5
5
5
P
P
P
4
4
4
-
-
-
I
I
I
h
h
h
Q
Q
Q
www.twitter.com/it_shades
http://www.facebook.com/ITShades-1184984251622300/ w w w . y o u t u b e . c o m / c h a n n e l / U C m f V P K O Q 2 I M E Q Q W 2 5 P 4 - I h Q
http://www.instagram.com/itshades1
w w w . y o u t u b e . c o m / c h a n n e l / U C m f V P K O Q 2 I M E Q Q W 2 5 P 4 - I h Q
http://www.facebook.com/ITShades-1184984251622300/ http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 / w w w . y o u t u b e . c o m / c h a n n e l / U C m f V P K O Q 2 I M E Q Q W 2 5 P 4 - I h Q

http://www.facebook.com/ITShades-1184984251622300/ http://www.instagram.com/itshades1 http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 / w

w
w
w
w
w
.
.
y
y
o
o
u
u
t
t
u
u
b
b
e
e
.
.
c
c
o
o
m
m
/
/
c
c
h
h
a
a
n
n
n
n
e
e
l
l
/
/
U
U
C
C
m
m
f
f
V
V
P
P
K
K
O
O
Q
Q
2
2
I
I
M
M
E
E
Q
Q
Q
Q
W
W
2
2
5
5
P
P
4
4
-
-
I
I
h
h
Q
Q
http://www.instagram.com/itshades1
w
w
w
w
w
w
w
w
w
w
w
w
.
.
.
.
y
y
y
y
o
o
o
o
u
u
u
u
t
t
t
t
u
u
u
u
b
b
b
b
e
e
e
e
.
.
.
.
c
c
c
c
o
o
o
o
m
m
m
m
/
/
/
/
c
c
c
c
h
h
h
h
a
a
a
a
n
n
n
n
n
n
n
n
e
e
e
e
l
l
l
l
/
/
/
/
U
U
U
U
C
C
C
C
m
m
m
m
f
f
f
f
V
V
V
V
P
P
P
P
K
K
K
K
O
O
O
O
Q
Q
Q
Q
2
2
2
2
I
I
I
I
M
M
M
M
E
E
E
E
Q
Q
Q
Q
Q
Q
Q
Q
W
W
W
W
2
2
2
2
5
5
5
5
P
P
P
P
4
4
4
4
-
-
-
-
I
I
I
I
h
h
h
h
Q
Q
Q
Q
http://www.instagram.com/itshades1 http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 /
http://www.facebook.com/ITShades-1184984251622300/ http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 /
w
w
w
w
w
w
.
.
y
y
o
o
u
u
t
t
u
u
b
b
e
e
.
.
c
c
o
o
m
m
/
/
c
c
h
h
a
a
n
n
n
n
e
e
l
l
/
/
U
U
C
C
m
m
f
f
V
V
P
P
K
K
O
O
Q
Q
2
2
I
I
M
M
E
E
Q
Q
Q
Q
W
W
2
2
5
5
P
P
4
4
-
-
I
I
h
h
Q
Q
http://www.facebook.com/ITShades-1184984251622300/ http://www.instagram.com/itshades1 http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 / w
w
w
w
w
w
.
.
y
y
o
o
u
u
t
t
u
u
b
b
e
e
.
.
c
c
o
o
m
m
/
/
c
c
h
h
a
a
n
n
n
n
e
e
l
l
/
/
U
U
C
C
m
m
f
f
V
V
P
P
K
K
O
O
Q
Q
2
2
I
I
M
M
E
E
Q
Q
Q
Q
W
W
2
2
5
5
P
P
4
4
-
-
I
I
h
h
Q
Q
w
w
w
w
w
w
w
w
w
w
w
w
.
.
.
.
y
y
y
y
o
o
o
o
u
u
u
u
t
t
t
t
u
u
u
u
b
b
b
b
e
e
e
e
.
.
.
.
c
c
c
c
o
o
o
o
m
m
m
m
/
/
/
/
c
c
c
c
h
h
h
h
a
a
a
a
n
n
n
n
n
n
n
n
e
e
e
e
l
l
l
l
/
/
/
/
U
U
U
U
C
C
C
C
m
m
m
m
f
f
f
f
V
V
V
V
P
P
P
P
K
K
K
K
O
O
O
O
Q
Q
Q
Q
2
2
2
2
I
I
I
I
M
M
M
M
E
E
E
E
Q
Q
Q
Q
Q
Q
Q
Q
W
W
W
W
2
2
2
2
5
5
5
5
P
P
P
P
4
4
4
4
-
-
-
-
I
I
I
I
h
h
h
h
Q
Q
Q
Q
http://www.instagram.com/itshades1 http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 / w w w . y o u t u b e . c o m / c h a n n e l / U C m f V P K O Q 2 I M E Q Q W 2 5 P 4 - I h Q
w
w
w
w
w
w
w
w
w
.
.
.
y
y
y
o
o
o
u
u
u
t
t
t
u
u
u
b
b
b
e
e
e
.
.
.
c
c
c
o
o
o
m
m
m
/
/
/
c
c
c
h
h
h
a
a
a
n
n
n
n
n
n
e
e
e
l
l
l
/
/
/
U
U
U
C
C
C
m
m
m
f
f
f
V
V
V
P
P
P
K
K
K
O
O
O
Q
Q
Q
2
2
2
I
I
I
M
M
M
E
E
E
Q
Q
Q
Q
Q
Q
W
W
W
2
2
2
5
5
5
P
P
P
4
4
4
-
-
-
I
I
I
h
h
h
Q
Q
Q
http : //w w w. l i n ke d i n . co m /i n /i t-s h ad e s -8 3 0 5 1 b 1 1 7 / w w w . y o u t u b e . c o m / c h a n n e l / U C m f V P K O Q 2 I M E Q Q W 2 5 P 4 - I h Q
w
w
w
w
w
w
w
w
w
.
.
.
y
y
y
o
o
o
u
u
u
t
t
t
u
u
u
b
b
b
e
e
e
.
.
.
c
c
c
o
o
o
m
m
m
/
/
/
c
c
c
h
h
h
a
a
a
n
n
n
n
n
n
e
e
e
l
l
l
/
/
/
U
U
U
C
C
C
m
m
m
f
f
f
V
V
V
P
P
P
K
K
K
O
O
O
Q
Q
Q
2
2
2
I
I
I
M
M
M
E
E
E
Q
Q
Q
Q
Q
Q
W
W
W
2
2
2
5
5
5
P
P
P
4
4
4
-
-
-
I
I
I
h
h
h
Q
Q
Q www.twitter.com/it_shades
http://www.facebook.com/ITShades-1184984251622300/ http://www.instagram.com/itshades1 w
w
w
w
w
w
.
.
y
y
o
o
u
u
t
t
u
u
b
b
e
e
.
.
c
c
o
o
m
m
/
/
c
c
h
h
a
a
n
n
n
n
e
e
l
l
/
/
U
U
C
C
m
m
f
f
V
V
P
P
K
K
O
O
Q
Q
2
2
I
I
M
M
E
E
Q
Q
Q
Q
W
W
2
2
5
5
P
P
4
4
-
-
I
I
h
h
Q
Q
http://www.facebook.com/ITShades-1184984251622300/ http://www.instagram.com/itshades1
w
w
w
w
w
w
w
w
w
w
w
w
.
.
.
.
y
y
y
y
o
o
o
o
u
u
u
u
t
t
t
t
u
u
u
u
b
b
b
b
e
e
e
e
.
.
.
.
c
c
c
c
o
o
o
o
m
m
m
m
/
/
/
/
c
c
c
c
h
h
h
h
a
a
a
a
n
n
n
n
n
n
n
n
e
e
e
e
l
l
l
l
/
/
/
/
U
U
U
U
C
C
C
C
m
m
m
m
f
f
f
f
V
V
V
V
P
P
P
P
K
K
K
K
O
O
O
O
Q
Q
Q
Q
2
2
2
2
I
I
I
I
M
M
M
M
E
E
E
E
Q
Q
Q
Q
Q
Q
Q
Q
W
W
W
W
2
2
2
2
5
5
5
5
P
P
P
P
4
4
4
4
-
-
-
-
I
I
I
I
h
h
h
h
Q
Q
Q
Q
Thankyou for reading our IByte.
Please feel free to subscribe to other

documents by signing up on
www.itshades.com

I-Byte Healthcare Industry

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

I-Byte Healthcare Industry

Uploaded by

Copyright:

Available Formats

IT Shades

I-Bytes Engage & Enable

ITShades.com has been founded with singular aim of engaging and

Aim of this IByte

This document brings together a set of latest data points and

1. Publishing of your company’s solutions/announcements in this document.

Feel free to contact us at marketing@itshades.com for any queries

Sponsoring Companies for this Edition

Feel free to contact us at marketing@itshades.com for any queries

3.Rewards and Recognition Updates........................14

4.Partnership Ecosystem Updates............................23

Feel free to contact us at marketing@itshades.com for any queries

Financial, M&A Updates

Feel free to contact us at marketing@itshades.com for any queries

FosunPharma Release 2019 Interim Results：Continue to Increase R&D Investment

Key Financial Highlights

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

Medtronic Reports First Quarter Financial Results

Key Financial Highlights

• Revenue of $7.5 Billion Increased 1.5% Reported; Increased

3.5% Constant Currency

• GAAP Diluted EPS of $0.64; Non-GAAP Diluted EPS of

• Company Raises FY20 EPS Guidance by 10 Cents

“Medtronic had a solid first quarter, delivering revenue

growth, operating margin expansion, and adjusted EPS

growth all ahead of expectations,” saidMedtronic

chairman and chief executive officer. “It’s a good start to

our fiscal year.”

Feel free to contact us at marketing@itshades.com for any queries

Amgen to Acquire Otezla® For $13.4 Billion In Cash,

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

Stryker announces definitive agreement to acquire

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

Boston Scientific Closes Acquisition of BTG plc.

Feel free to contact us at marketing@itshades.com for any queries

Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

Feel free to contact us at marketing@itshades.com for any queries

Regeneron Debuts on Prestigious Dow Jones Sustainability

Regeneron Pharmaceuticals, Inc. announced that the

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

Roche receives FDA clearance for cobas pro integrated solutions

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

Medtronic Introduces Envision™ Pro Continuous Glucose

announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system

— a fully disposable, zero calibration professional CGM system — has

obtained CE (ConformitéEuropéenne) Mark approval. Medtronic will begin

regulatory requirements1. This new technology will empower healthcare

fingersticks. Also, there is no need to return the sensor or recorder to their

wirelessly with the patient’s smartphone allowing automatic data uploading so

remotely without additional in-office visits.

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

European Commission approves Roche’s Tecentriq in combination with Abraxane

For more details, please click the link below:

Feel free to contact us at marketing@itshades.com for any queries

European Commission approves Roche’s new Tecentriq-based combination therapy

For more details, please click the link below: